Chargement en cours...
Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived
BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797–9. ©2018 AACR....
Enregistré dans:
| Publié dans: | Cancer Discov |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6345252/ https://ncbi.nlm.nih.gov/pubmed/29967074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0489 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|